CorMedix Inc (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercialising therapeutic products for life-threatening diseases and conditions, has entered into a definitive agreement to acquire Melinta Therapeutics LLC, a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, the two companies announced on Thursday.

The agreed purchase price is USD300m in upfront consideration, comprising USD260m in cash and USD40m in CorMedix equity issued to Melinta shareholders. The deal also includes an additional regulatory milestone payment of up to USD25m and tiered royalties on REZZAYO US net sales, along with low-single-digit royalties on MINOCIN for injection.

This acquisition will add six marketed infectious disease therapies and one cardiovascular product, significantly expanding CorMedix's hospital- and clinic-focused portfolio.

Melinta's lead product, REZZAYO, is approved for candidemia and invasive candidiasis and is in Phase III trials for prophylactic use in transplant patients, with results expected in the first half of 2026.

Since its 2020 privatisation by Deerfield Management, Melinta has achieved 85% revenue growth, positive cash flow, and expanded global partnerships.

The acquisition also brings Melinta's experienced team and established hospital presence into CorMedix's operations.

The transaction, approved by both companies' boards, is subject to regulatory clearance and is expected to close in September 2025.